Is Yttrium 90 Ibritumomab Tiuxetan safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Yttrium 90 Ibritumomab Tiuxetan. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
Relevant published information was not found as of the revision date.
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Yttrium-90 decays by emission of beta particles, with a physical half-life of 64.1 hours and a decay energy of 2.28 MeV.
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.